Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma, Inc. (Nasdaq: SILO) regularly issues news updates that reflect its dual identity as a developmental-stage biopharmaceutical company and a cryptocurrency treasury company. Its press releases highlight progress in drug development for stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, alongside announcements about its evolving digital assets treasury strategy.
On the biopharmaceutical side, Silo’s news flow centers on SPC-15, an investigational intranasal serotonin 5-HT4 receptor agonist being developed for PTSD and stress-induced anxiety. Recent releases describe IND-enabling toxicology and toxicokinetic work, large animal safety studies, drug-device evaluations of a soft mist nasal spray system, and plans for Phase 1 single ascending dose and multiple ascending dose studies. The company also reports on regulatory strategy, including its intention to pursue the FDA’s 505(b)(2) pathway, and on collaborations with organizations such as Allucent and Columbia University.
News items also cover Silo’s broader pipeline, including SP-26 for fibromyalgia and chronic pain and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Investors following SILO news can expect updates on preclinical data, clinical trial preparations, intellectual property expansion, and strategic academic and CRO partnerships.
In parallel, Silo’s releases describe the launch and build-out of its digital assets treasury. Announcements detail initial purchases of Bitcoin, Ethereum, Solana, and ResearchCoin, the establishment of a Crypto Advisory Board, engagement of Fireblocks for institutional-grade custody and infrastructure, and allocation to the Alphaledger T12 Fund for tokenized real-world asset exposure on the Solana blockchain. Additional disclosures include software and domain acquisitions related to crypto applications and updates on treasury diversification objectives.
Visitors to the SILO news page can use this stream of company-issued information to track clinical milestones, regulatory steps, capital markets activity, and digital asset strategy developments over time.
Silo Pharma (Nasdaq: SILO), a developmental stage biopharmaceutical company, has announced a $2.5 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 2,857,143 shares of common stock at $0.875 per share.
Additionally, Silo will issue unregistered warrants in a concurrent private placement to purchase up to 2,857,143 shares at an exercise price of $0.75 per share. These warrants will be immediately exercisable and expire after five years. The offering, managed by H.C. Wainwright & Co. as exclusive placement agent, is expected to close around October 1, 2025.
The company plans to use the net proceeds for working capital and general corporate purposes.
Silo Pharma (Nasdaq: SILO), a developmental-stage biopharmaceutical and cryptocurrency treasury company, has initiated implementation of its strategic agreement with Fireblocks for crypto treasury management. Fireblocks, a leading digital asset custody platform, has facilitated over $10 trillion in secure transfers to date.
The partnership aims to establish institutional-grade infrastructure for buying, staking, and managing digital assets at scale. Fireblocks' multi-layer security framework incorporates multi-party computation technology, Intel SGX, a signature policy engine, and deposit address authentication network.
Silo Pharma (Nasdaq: SILO), a developmental-stage biopharmaceutical and cryptocurrency treasury company, has partnered with Fireblocks as its institutional crypto treasury platform custodian. The strategic agreement aims to enhance Silo's digital asset management capabilities for Bitcoin, Ethereum, and Solana.
Fireblocks, which has facilitated over $6 trillion in secure transfers, will provide enterprise-grade security through its multi-layer framework, combining multi-party computation technology, Intel SGX, and deposit address authentication. This infrastructure will support Silo's long-term strategy for buying, staking, trading, and managing digital assets.
Silo Pharma (Nasdaq: SILO) has initiated its cryptocurrency treasury strategy with its first purchases of Ethereum (ETH) and Solana (SOL) tokens. The company, which operates as a developmental-stage biopharmaceutical and cryptocurrency treasury company, plans to stake these tokens for revenue generation and capital appreciation.
CEO Eric Weisblum expressed confidence in decentralized blockchain and DeFi platforms, highlighting the company's commitment to incorporating digital assets into its treasury holdings. This strategic move aims to support Silo's biopharmaceutical assets development while positioning the company for blockchain and real-world asset tokenization initiatives.
Silo Pharma (Nasdaq: SILO) has strengthened its intellectual property portfolio with a new Japanese patent (No. 7683882) granted to its research partner Columbia University for SPC-15, the company's lead PTSD treatment. The patent, which follows a recent Australian patent grant, covers serotonin 4 receptor agonists for stress treatment.
The intranasal PTSD treatment, exclusively licensed to Silo by Columbia University, gains additional international protection through this patent issuance, supporting the company's development and regulatory strategy for this novel therapy.
Silo Pharma (Nasdaq: SILO) has secured a significant patent in Australia (patent number 2020271839) for its PTSD drug candidate SPC-15. The patent, granted to Silo's research partner Columbia University, covers the invention "Prophylactic efficacy of serotonin 4 receptor agonists against stress" which is exclusively licensed to Silo.
SPC-15, the company's lead asset, is being developed as an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent strengthens Silo's global intellectual property portfolio and supports their plans for clinical trial development of this innovative therapeutic approach to preventing stress-induced disorders.
Silo Pharma (Nasdaq: SILO) announced the publication of preclinical research for its Alzheimer's disease therapeutic SPC-14 in the prestigious journal Alzheimer's Research & Therapy. The study demonstrates that SPC-14, a combination of (R,S)-ketamine with prucalopride, showed promising results in treating cognitive decline in Alzheimer's disease.
The research, co-authored by CEO Eric Weisblum, revealed that SPC-14 improved memory retrieval in mouse models. The therapeutic was developed under a sponsored research agreement with Columbia University, from which Silo obtained an exclusive global license in 2024 for development, manufacturing, and commercialization. The targeted Alzheimer's disease treatment market is projected to reach $30.8 billion by 2033, growing at a 18.8% CAGR.
Silo Pharma (Nasdaq: SILO) announced positive safety results for its PTSD drug candidate SPC-15 in a FDA-requested 7-day large animal safety study. The intranasal spray formulation demonstrated local and systemic safety with no toxicities at clinical-representative doses, showing comparable systemic exposure to standard oral administration.
The company is pursuing FDA approval through the 505(b)(2) pathway, which could streamline the approval process by leveraging existing safety data. Silo is currently conducting IND-enabling GLP toxicology studies and evaluating clinical trial sites. The PTSD market, valued at $1.8 billion in 2024, is projected to reach $3.2 billion by 2034.
Silo Pharma (Nasdaq: SILO) has announced a strategic expansion into cryptocurrency treasury management, focusing on Bitcoin, Ethereum, and Solana. The company has appointed crypto infrastructure expert Corwin Yu as the first member of its new Crypto Advisory Board to spearhead this initiative.
The strategy includes opportunistic digital currency purchases and yield generation through staking, supported by newly acquired AI-powered market intelligence technology. Simultaneously, Silo Pharma continues its biopharmaceutical focus, with its PTSD drug SPC-15 approaching FDA IND application submission.
Silo Pharma (Nasdaq: SILO) has completed dosing in a FDA-requested 7-day safety and toxicology large animal study for its lead PTSD drug candidate SPC-15. The bioanalytical and safety/toxicology results are expected within 60 days.
The company is progressing with two remaining preclinical studies: an IND-enabling GLP-compliant toxicology study and a device study for SPC-15's microchip-based nasal spray system. Silo plans to pursue the FDA's 505(b)(2) regulatory pathway for SPC-15's approval, which could potentially accelerate clinical timelines and reduce development costs.